Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

Prof. dr. rudolf prager - publikationen

Univ.-Prof. Dr. Rudolf Prager
Literaturliste
Original- und Übersichtsarbeiten:
Punzengruber C, Prager R, Kolassa N, Winkler F, Suko J : Calcium gradient dependent and calcium gradient independent phosphorylation of sarcoplasmic reticulum by orthophosphate . The role of magnesium .Eur. J. Biochem. 92, 349 - 359, 1978. Prager R, Punzengruber C, Kolassa N, Winkler F, Suko J : Ionized and bound calcium inside isolated sarcoplasmic reticulum of skeletal muscle and its significance in phosphorylation of adenosine triphosphatase by orthophosphate. Eur. J. Biochem. 97, 239 - 250, 1979. Schernthaner G, Müller MM, Prager R, Mühlhauser I : Die klinische Bedeutung des Glycohämoglobins ( HbA1 ). Wien. klin. Wschr. 92, 1-11, 1980. Prager R, Schernthaner G, Müller MM : HDL - Cholesterin und Diabetes mellitus. Analyse von Diabetestyp, Therapieform, Diabetesdauer und Stoffwechselkontrolle. Wien. klin. Wschr. 92, 672 - 677, 1980. Kuzmits R, Schernthaner G, Mühlhauser I, Prager R, Müller MM : Metabolismus der Schilddrüsenhormone und diabetische Stoffwechselkontrolle. Bulletin S.S.C.C./ S.G.K.C. 21, 170- 178, 1980. Prager R, Schernthaner G, Mühlhauser I, Müller MM . Einfluss von Diabetestyp, Stoffwechselkontrolle ( HbA1 ), Therapieform und Diabetesdauer auf HDL - Cholesterin und Plasmalipide bei Typ - I und Typ - II Diabetes mellitus. Verh. Dt. Ges. Inn. Med. 86, 991 - 994, 1980. Prager R, Schernthaner G, Meisinger V, Mühlhauser I, Müller MM : Hypomagnesiämie - ein möglicher Angiopathierisikofaktor - und metabolischer Kontrollgrad bei Diabetes mellitus. Acta med. Austriaca 7, 203 - 204, 1980. Prager R, Schernthaner G, Kostner CM, Mühlhauser I, Dieplinger H, Lang PD : Plasmalipide, Lipoproteine, Apolipoproteine und LCAT bei Diabetes mellitus : eine Doppelblind Crossover Studie mit Bezafibrat. Verb.Dt.Ges.Inn.Med. 7, 992 - 995, 1981. Klein K, Sinzinger H, Schernthaner G, Silberbauer K, Prager R : Plättchensensitivitat fur Prostacyclin ( PG 12 ) bei Patienten mit juvenilem Diabetes mellitus. Wien. klin. Wschr. 93, 460 - 462, 1981. 10. Laggner P, Suko J, Punzengruber C, Prager R : Electron spin resonance studies on conformational changes of the sarcoplasmic reticulum Ca2 - ATPase induced by synergistic action of calcium and ATP. Zeitschr. f. Naturforschung 36b, 1136- 1143, 1981. 11. Prager R, Schernthaner G, Kostner GM, Mühlhauser I, Zechner R, Dorda W : Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins Al, All and B and LCAT activity in hyperlipidemic, non insulin dependent diabetics. Artherosclerosis 43, 321 - 327, 1982. 12. Prager R, Schernthaner G, Kostner G, Mühlhauser I, Meisinger V: Hypomagnesiämie bei Diabetes mellitus. Korrelationsanalysen mit Stoffwechselkontrollgrad, Lipidstatus und Thrombozytenfunktion. Akt. Endocrin. Stoffw. 3, 140 - 143, 1982. 13. Schernthaner G, Borkenstein M, Mathae R, Mayr WR, Hohenecker J, Prager R, Schober G, Susani M : Semisynthetisches und biosynthetisches Humaninsulin : Immunogenitätsuntersuchungen nach Langzeittherapie bei Typ - I Diabetikern und Bindungsanalysen an praformierten lgG Insulinantikörpern und Insulinrezeptoren.In "Neue Insuline :1.Internationales Symposion 1982 "Herausg. Petersen KG, Schluter KJ, Kerp L.: 140-148. 14. Prager R, Schernthaner G : Comparison of insulin receptor binding to monocytes and erythrocytes in newly diagnosed type II diabetes mellitus. Horm. metab. Res. 14, 561-563, 1982. 15. Luger A, Graf H, Prager R, Stummvoll HK : L’hemofiltration continue sur membrane de polysulfone. La Nouvelle Presse Medicale 11, 3657, 1982. 16. Prager R, Schernthaner G : Receptor binding properties of human insulin (recombinant DNA and human proinsulin and their interaction at the receptor site . Diabetes Care 5, Suppl. 104 - 106, 1982. 17. Stummvoll HK, Graf H, Ebm W, Luger A, Prager R, Wolf C : Allgemeine internistische Intensivmedizin - erste Erfahrungen an der neu eröffneten Intensivstation der ll. Medizinischen Universitätsklinik Wien. Acta med. Austriaca 9, 166-169, 1982. 18. Schernthaner G, Graninger W, Kwasny W, Prager R, Otto C : Diabetestherapie mittels kontinuierlicher Insulininfusion durch portale Pumpen : Metabolische Effekte der Kurzzeitbehandlung und Langzeitergebnisse bei Problempatienten . Acta. med. Austriaca 9, 205-213, 1982. 19. Graf H, Luger A, Prager R, Stummvoll HK : Stimulation of anti-glomerular basement membrane antibody production by plasma exchange in Good-pastures syndrome. In: 2nd Mitteleuropean Meeting on Nephrology Dialysis and Transplantation . Eds. : Barduagnis S, Pitzorno F, Rocco A . Wichtig Editore, Milano 257-259, 1982. 20. Graf H, Stummvoll HK, Luger A, Prager R: Effect of amino acid infusion on glomerular filtration rate. N. Engl. J. Med. 308, 159-160, 1993. 21. Prager R, Schernthaner G: Insulin binding of human and porcine monocomponent insulin to monocytes in type I ( insulin dependent ) diabetic patients and control subjects. Diabetologia 25, 235-237, 1983. 22. Prager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonseder R: Peripheral Insulin Resistance in Primary Hyperparathyreoidism. Grune & Stratton, Inc. 1983. 23. Kwasny W, Otto C, Prager R, Knoflach F, Schernthaner G: Kombinationstherapie von Insulin und Sulfonylharnstoff (HB 420) bei übergewichtigen, insulinresistenten Typ II-Diabetikern: Analyse von Insulinrezeptorbindung, Insulinsekretion und Stoffwechselkontrollgrad. Kombinationstherapie Insulin/Sulfonylharnstoff, Karger, Basel 1983. Hrsg. W.Bachmann und H.Mehnert (München). 24. Schernthaner G, Kovark J, Prager R, Willvonseder R: Growth Hormone, prolactin and insulin following arginine infusion in primary hyperparathyreoidism before and after parathyeroidectomy. Acta Endocrinologica 104, 206-209, 1983. 25. Stummvoll HK, Graf H, Luger A, Prager R: Spontaneous arteriovenous plasma separation. Critical Care Medicine 10, 1983. 26. Graninger W, Prager R, Schernthaner G: Einfluss der kontinuierlichen Insulininfusion mittels tragbarer, programmierbarer Insulinpumpen auf das Insulinrezeptorverhalten. Verb.Dt.Ges.Inn.Med. 89, 721-723, 1983. 27. Schernthaner G, Kostner GM, Dieplinger H, Prager R, Mühlhauser I: Apolipoproteins (AI, AII, B), lipoprotein (a) and lecithin cholesterol – acetyltransferase activity in diabetes mellitus. Atherosclerosis 49, 277–293, 1983. 28. Prager R, Schernthaner G : Insulin receptor binding to monocytes, insulin secretion and glucose tolerance following metformin treatment . Results of a double blind cross over study in type II diabetics. Diabetes 32, 1083-1086, 1983. 29. Ertl L, Prager R : Gesichts - und Mediastinalemphysem im Anschluss an Zahnextraktion. Österr. Z. Stomatol. SO, 340-342. 1983. 30. Graf H, Stummvoll HK, Prager R, Luger A, Kovarik J : Protein binding and dialysate concentration of aluminum - the major determinants of aluminum kinetics during hemodialysis. Chemical Toxicology and Clinical Chemistry of Metals. S.S. Brown, J. Savory Eds. Academic Press, London - New York, 357-360, 1983. 31. Luger A, Graf H, Prager R, Stummvoll HK : Die kontinuierliche arteriovenöse Hämofiltration als Therapie der akuten Niereninsuffizienz . Wr. Klin. Wschr. 96,1-4 1984. 32. Prager R, Schernthaner G, Kovarik J, Cichini G, Klaushofer K, Willvonseder R : Primary hyperparathyreoidism is associated with decreased insulin receptor binding and glucose intolerance. Calcif. Tissue Int. 36, 253-258, 1984. 33. Luger A, Graf H, Prager R, Stummvoll HK : Alterations in the renin - angiotensin -aldosterone system in the critically Ill . Horm. metabol. Res. 16, 213-214, 1984. 34. Schernthaner G, Prager R : Insulinrezeptor - und Postrezeptorstörungen : Bedeutung für Entstehung und Therapie von Kohlenhydratstoffwechselstörungen. Acta med. Austriaca 1, 70-77, 1984. 35. Schernthaner G, Prager R, Weissel M, Höfer R : Decreased insulin receptor binding in hyperthyreoidism. Klin. Wschr. 62 : 1074-1080, 1984. 36. Schernthaner G, Prager R, Punzengruber C, Luger A : Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28, 138-142, 1985. 37. Graf H, Prager R, Kovarik J, Luger A, Schernthaner G, Pinggera WF: Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis . Metabolism 34 : 974-977, 1985. 38. Prager R, Schernthaner G, Graf H, Chichini G, Luger A : Influence of acute experimental hypercalcemia on peripheral insulin sensitivity in healthy subjects . Diabetes Research 3 : 199 – 20, 1986. 39. Prager R, Schernthaner G, Graf H : Effect of metformin treatment on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete & Metabolisme 12 : 346-350, 1986. 40. Prager R, Wallace P, Olefsky JM : In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J. Clin. Invest. 7S: 472-481, 1986. 41. Baron A, Wallace P, Brechtel G, Prager R: Somatostatin does not increase Insulin-stimulated Glucose Uptake in Humans. Diabetes 36, 33–36, 1987. 42. Prager R, Wallace P, Olefsky JM : Hyperinsulinemia Does not compensate for peripheral Insulin Resistance in Obesity. Diabetes 36, 327–334, 1987. 43. Bergman RN, Prager R, Volund A, Olefsky JM : Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic Glucose clamp. J. Clin. Invest. 79, 790-800, 1987. 44. Prager R, Wallace P, Olefsky JM : Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes 36, 607-61, 1987. 45. Prager R : Receptor and postreceptor abnormalities in diabetes. In Clinical Immunology International Congress Series 718 Ed. Pruzanski W. Seligmann M. Excerpta Medica, Amsterdam - New York Oxford, 35-41, 1987. Arbeiten nach der Habilitation:
46. Bratusch Marrain P, Prager R, Kacerovsky-Bielesz G, lrsigler K, Borkenstein M, Biesenbach G, Kitzler P, Hopferwieser Th, Pretsch I, Sulzer M : Stand der Betreuung der Typ - I -Diabetiker in Österreich. Wien.Klin.Wschr. 100, 442-449,1988. 47. Klauser R, Schernthaner G, Prager R : Mixtures of human intermediate and human regular insulin in type I diabetic patients. Diabetes Research and Clinical Practice 5,185-190, 1988. 48. Prager R : Pathogenese und Therapie des Diabetes mellitus Typ I und Typ II. 49. Baron AD, Kolterman OG, Prager R, Freidenberg GR, Henry RR, Garvey WT, Olefsky JM : Mechanisms of insulin resistance in obese and type II diabetic subjects. In Diabetes Mellitus : Pathophysiology and Therapy. Ed. Creutzfeld W. And Lefebre P., Springer Verlag Berlin-Heidelberg-New York-London-Paris-Tokyo, 107-126, 1988. 50. Schnack C, Prager R, Winkler J, Klauser R, Schernthaner G : Effects of 8 Wk a- Glucosidase inhibition on metabolic control, c - peptid secretion, hepatic glucose output and peripheral insulin sensitivity in poorly controlled type II Diabetic patients. Diabetes Care 12, 537-543, 1989. 51. Prager R : Therapie der Hyperlipidämie mit HMG - CoA – Reduktasehemmern. Wien.med. Wschr. 139, Suppl. 105, 17-20,1989. 52. Klauser R, Mühlbacher F, Gnant M, Prager R, Brauner E, Pacini G, Kovarik J : Pancreatic transplantation with venous portal drainage. Lancet, 988, 1989. 53. Klauser R, Prager R, Watschinger B, Schernthaner G : Metabolic effects of biosynthetic human proinsulin in type II diabetes mellitus. Europ. J. Clin. Invest. 19, 466-479, 1989. 54. Prager R, Schernthaner G, Niederle B, Roka R: Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyreoidism before and after surgery. Calc. Tissue Intern 46: 1-4, 1990. 55. Kueenburg H, Brunnbauer M, Watzinger U, Winter F. Müller MM, Graf H., Prager R. : Die Wertigkeit von Fruktosamin bei Hämodialysepatienten. Wien. Klin. Wschr.: 102, Suppl. 180, 11-13. 1990. 56. Brunnbauer M, Kuenburg E, Winter F, Müller MM, Prager R : Tageszeitliche Schwankungen von Fruktosamin bei Patienten mit Typ - II Diabetes mellitus . Wien. Klin. Wschr. 102, Suppl. ISO, 72-73, 1990. 57. Hartter E, Svoboda T, Leil B, Schuller M, Ludvik B, Woluzczuk W, Prager R : Reduced islet - amyloid polypeptide in insulin - dependent diabetes mellitus. Lancet , 854, 1990. 58. Prager R : Warum das Insulin beim Typ - II Diabetiker nicht richtig zur Wirkung 59. Klauser R, Speiser P, Gisinger C, Schernthaner G, Prager R : Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J. Cardiovasc. Pharmacol. 15, Suppl. 1, 93-96,1990. 60. Mühlbacher F, Gnant MFX, Auinger M, Steininger R, Klauser R, Prager R, Karnel F : Pancreatic venous drainage to the portal vein: A new method in human pancreas transplantation. Proceedings 22, 636-637, 1990. 61. Luger A, Prager R, Gaube S, Graf H, Klauser R, Schernthaner G : Decreased peripheral insulin sensitivity in acromegalic patients. Exp. Clin. Endocrinol. 95, 339-343, 1990. 62. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kueenburg E, Brunnbauer M, Woloszczuk W, Prager R : Basal and stimulated plasma levels of pancreatic amylin indicate its co - secretion with insulin in humans. Diabetologia 34 ,52-54,1991. 63. Sachs G, Spiess K, Moser G, Prager R, Kunz A, Schernthaner G : Glykosiliertes Hämoglobin und Glukose - Selbstmonitoring ( Compliance ) bei depressiven und nicht depressiven Typ 1- Diabetikern. Psychother., Psychosom. med. Psychol. 41, 306-312, 1991. 64. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C Kueenburg E, Schernthaner G : Metabolic Effects of Isradipine vs. Hydrochlorothiazide in Diabetes mellitus. Hypertension 1, 15-21, 1991. 65. Prager R, Ludvik B, Hartter E : Die Rolle von Amylin in der Pathogenese des Typ- II-Diabetes mellitus. Acta Medica Austriaca IS, 61-62, 1991. 66. Mihaljevic R, Bratusch-Marrain P, Hoffmann H, Langmayr N, Prager R : Patientengerechte Insulinapplikation bei Typ II- Diabetikern. Therapiewoche Österreich 6, 7, 487-496, 1991. 67. Klauser R, Prager R, Schernthaner G, Olefsky JM : Contribution of postprandial insulin and glucose to glucose disposal in normal and insulin-resistant obese subjects. J. Clin. Endocrin. Metab. 73, 258-264, 1991. 68. Watschinger B, Brunner Ch, Schnack Ch, Prager R, Weissel M, Burghuber OC : Left and right ventricular function in normotensive type I diabetic patients. In: Cardionephrology , Eds.: M.Timio, V. Wizemann. Wichtig Editore, ISBN 88-85053-92-0, p. 115-118, 1991. 69. Ludvik B, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes mellitus. Diabetes 40,1615-1619,1991. 70. Ludvik B, Kuenburg E, Brunnbauer M, Schernthaner G, Prager R : The Effects of Ramipril on Glucose Tolerance, Insulin Secretion, and insulin Sensitivity in patients with Hypertension. J. of Cardiovasc. Pharm. 18, Suppl. 2, 157-159, 1991. 71. Virgolini I, Angelberger P, Banyai M, Knöbl P, Pantev T, Neuhold N, Prager R, Sinzinger H: 123 I- tyrosine- ( A 14 )-insulin: preparation and preliminary clinical studies. Wien.klin. Wschr. 103 , 657-60, 1991. 72. Ludvik B, Kautzky-Willer A, Prager R : Epidemiologie, Ätiologie und neue therapeutische Konzepte bei Adipositas. Therapiewoche Österreich,7,10-16,1992. 73. Kautzky-Willer A, Pacini G, Niederle B, Schernthaner G, Prager R: Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyreoidism before and after surgery. Clinical Endocrinology 37,147-155,1992. 74. Niederle B, Stamm L, Längle F, Schubert E, Woluszczuk W, Prager R : Primary hyperparathyreoidism in Austria: Results of an 8 year prospective study. World J. Surgery 16, 777-783, 1992. 75. Kautzky-Willer A, Pacini G, Ludvik B, Schernthaner G, Prager R: B cell hypersecretion and not reduced hepatic extraction causes hyperinsulinemia in obese nondiabetic subjects. Metabolism 41:1304-1312,1992. 76. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R : Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36:84-87,1993. 77. Prager R : Amylin und Typ II-Diabetes. Diabetes und Stoffwechsel 2,40- 78. Kautzky-Willer A, Niederle B, Schernthaner G, Prager R: Diabetes mellitus und Kohlenhydratstoffwechsel beim primaren Hyperparathyreoidismus. Wien. Klin. Wschr. 105/6, 158-162,1993. 79. Watschinger B, Brunner Ch, Wagner A., Schnack Ch, Prager R, Weissel M, Burghuber OC : Left ventricular diastolic Impaired in type I diabetic patients with microalbuminuria. Nephron 63, 145-151, 1993. 80. Prager R, Streli C. Prager R : Diabetes und Sport Wr. Med. Wschr. 143, 9-12, 81. Kautzky-Willer A, Pacini G, Weissel M, Capek M, Ludvik P, Prager R: Elevated hepatic insulin extraction in essential hypertension. Hypertension 21: 646- 653,1993. 82. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M: Thrombogenic factors are related to urinary albumin excretion rate in type I (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 1045-1050,1993. 83. Kautzky-Willer A, Endler AT, Streli C, Graf H, Prager R: Glycated hemoglobin in hemodialysis patients with and without erythropoietin substitution: a method comparison. Klin. Lab. 39,1-3,1993, S.1046. 84. Kautzky-Willer A, Capek M, Weissel M, Ludvik B, Prager R, Pacini G: Insulin sensitivity, secretion and hepatic extraction in untreated hypertensive patients. In: Current Topics in Diabetes research (Editors: F.Belfiore.R. N. Bergman, G. M. Molinatti ). Karger, Basel 1993, 250-253. 85. Sachs G, Spiess K, Moser G, Kautzky-Willer A, Lugner A, Pietschmann P, Schernthaner G, Prager R : Hormonal and blood glucose responsiveness as an indicator of specific emotional arousal in Type I diabetics. J. Psychosom. Res. 37, 831-842, 1993. 86. Kautzky-Willer A, Tomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W, Prager R: Role of islet amyloid polypeptide secretion in insulin resistant humans. Diabetologia 37,188-194,1994. 87. Schnack Ch, Capek M, Banyai M, Kautzky-Willer A, Prager R , Schernthaner G: Long term treatment with nifedipine reduces urinary albumin excretin rate in treatment in normotensive type-1 diabetic patients with microalbuminuria. Acta Diabetologica Latina 31, 14-18,1994. 88. Schnack Ch, Pietschmann P, Knöbl P, Schuller E, Prager R, Schernthaner G : Apolipoprotein ( a ) levels and artherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus . Nephron 66, 273-277, 1994. 89. Knöbl P, Pietschmann P, Schnack C, Prager R, Schernthaner G: Apolipoprotein (a) levels in patients with type I diabetes mellitus are unrelated to metabolic control or vascular disease. Wien.klin.Wschr.: 106, 728-732, 1994. 90. Ludvik B, Lell B, Hartter E, Stifter S, Graf H, Prager R: Increased of circulating amylin in patients with chronic renal failure have no effect on insulin secretion. J.Clin.Invest. 94, 2045-2050, 1994. 91. Spiess K, Sachs G, Frischenschlager O, Moser G, Schernthaner G, Prager R: Zur phasenspezifischen Funktion der Vorbeugung beim Typ I Diabetes- Patienten nach Krankheitsausbruch. Z. Psychosom. Med Psychoanal. 40, 52-67,1994. 92. Spiess K, Sachs G, Moser G, Pietschmann P, Schernthaner G, Prager R: Psychological moderator variables and metabolic control in recent onset type I diabetic patients – a two year longitudinal study. J Psychosom. Res , 38, 249 - 258, 1994. 93. Capek M, Schnack C, Ludvik B, Kautzky-Willer A, Banyai M, Prager R: Effect of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria. Clin. Investig. 72, 961-966,1994. 94. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T: Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb. Haemostas. 71, 692-697, 1994. 95. Prager R: Diabetes state of the art. Ungelöste Probleme und Zukunftsperspektiven. Hausarzt 5, 6-8, 1994. 96. Prager R: Stufentherapie des Diabetes mellitus Typ II. Forum Dr. Med. 1842- 97. Pacini G, Tomaseth K, Kautzky-Willer A, Prager R: An integrated mathematical models of islet amyloid polypeptide dynamics. Modeling and control in Biomedical Systems. B.W. Patterson (Ed.) Omnipress, Madison WI, 377-378, 1994. 98. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney International 47, 200-206, 1995. 99. Griesmacher A, Kindhauser M, Andert S, Schreiner W, Toma C,Knöbl P, Pietschmann P, Prager R, Schnack C, Schernthaner G, Müller MM : Enhanced serum levels of thiobarbituric-acid reactive substances in diabetes mellitus. Am. J. Med. 98, 469 – 475, 1995. 100. Prager R: Adipositas: Physiologie und Behandlungsmöglichkeiten. Acta med. 101. Geyer G, Haidinger G, Francesconi M, Langmayr N, Prager R, Schoberberger R, Toplak H, von Kalkreuth G, Kunze M: Der Einfluss von Dexfenfluramin auf Essverhalten und Körpergewicht von Adiposenergebnissen einer Anwendungsstudie von Isomeride in österreichischen Artzpraxen. Acta med. Austriaca 22, 95-109, 1995. 102. Spiess K, Sachs P, Pietschmann P, Prager R: Program to reduce onset distress in unselected type I diabetic patients : effects on psychological variables and metabolic control. Europ. J. Endocrinol. 132, 580-586, 1995. 103. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G: An integrated mathematical model to assess B-cell activity during the oral glucose test. Am.J.of Physiol.270, E522-E531, 1996. 104. Kotzmann H, Linkesch M, Ludvik B, Clodi M, Luger A, Schernthaner G, Prager R, Klauser R: Effect of danazole-induced hyperglucagonemia on glucose tolerance. Europ.J.of Clini.lnvest. 25, 942-947,1996. 105. Kautzky-Willer A, Tomaseth K, Clodi M, Ludvik B, Waldhäusl W, Prager R, Pacini G: Dexamethasone treatment enhances beta cell activity in healthy humans. Metabolism 45, 486-491, 1996. 106. Bamas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, lrsigler K, Mayer G: Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control. Diabetologia 40, 327-331, 1997. 107. Tomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ, Prager R, Olefsky JM, Ludvik B: Amylin release during oral glucose tolerance test. Diabetic Medicine 14, Suppl 2, 29-34,1997. 108. Ludvik B, Kautzky-Willer A, Prager R, Tomaseth K, Pacini G.: Amylin, History and overview. Diabetic Medicine 14, Suppl. 2, 9-13,1997. 109. Kautzky-Willer A, Tomaseth K, Ludvik B, Nowotny P, Rabensteiner D, Waldhäusl W, Pacini G, Prager R: Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes 46, 607-614, 1997. 110. Kautzky-Willer A, Prager R, Waldhäusl W, Pacini G, Tomaseth K, Wagner OF, Ulm M , Streli C, Ludvik B: Pronounced insulin resistance and inadequate 6 cell secretion characterize lean gestational diabetes mellitus during and after pregnancy. Diabetes Care 20, 1619-1623,1997. 111. Clodi M, Thomaseth K, Pacini G, Hermann A, Kautzky-Willer A, Waldhäusl W, Ludvik B, Prager R: Distribution and kinetics of amylin in humans. Am.J.Physiol. 274, E 903-908. 1998. 112. Fliser D, Pacini G, Engelreiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and Hyperinsulinemia in Patients with incipient renal disease. Kidney Intern 53, 1343-1347, 1998. 113. Rabensteiner D, Abrahamian H, Irsigler K, Hermann K, Kiener H, Mayer G, Kaider A, Prager R: ACE Gene Polymorphismus and Proliferative Retinopathy in type 1 Diabetes. Diabetes Care 22, 1530-1535, 1999. 114. Tura A, Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G: Modelling beta cell secretion and kinetics of proinsulin during an oral glucose test.Health Sciences simulation 2000, Anderson JK and Katzper M. (Eds.), SCS Press, San Diego, USA 103-108, 2000. 115. Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager R, Luger A: The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. Europ. J.Clini.Invest. 30, 771-778, 2000. 116. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, Prager R und Waldhäusl W: Increased plasma leptin in gestational diabetes. Diabetologia 44, 164-172, 2001. 117. Ludvik B, Mahdjoobian K, Waldhäusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G: The Effect of Ipomoea batatas (Caiapo) on Glucose Metabolism and Serum Cholesterol in Patients with Type 2 Diabetes. A randomized study. Diabetes Care 25, 239-240, 2002. 118. Abrahamian H, Prager R: Senkung der kardiovasculären Morbidität und Mortalität durch antihypertensive Kombinationstherapie bei Patienten mit Typ 2-Diabetes mellitus. Wien.Med.Wochenschr 159, 210-214, 2002. 119. Georg P, Kautzky-Willer A, Mahjoobian K, Hofer A, Prager R, Pacini G, Ludvik B: Influence of Metabolic Control on Splanchnic Glucose Uptake, Insulin Sensitivity, and the Time Required for Glucose Absorption in Patients with Type 1 Diabetes. Diabetes Care 25, 2042-2047, 2002. 120. Abrahamian H, Schueller A, Mauler H, Prager R, Irsigler K: Transfer of knowledge from the specialist to the generalist by videoconferencing: effect on diabetes care. J Telemed Telecare 8, 350-355, 2002. 121. Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM: Acute-phase response and immunological markers in morbid obese patients following adjustable gastric banding. Int.J.Obes.Relat.Metab.Disord. 27, 355-361, 2003. 122. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess ß-cell function during OGTT in metabolic disorders. Am.J.Physiol. 285, E 155-162, 2003. 123. Ludvik B, Tomaseth K, Nolan Jj, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagons secretion in healthy and diabetic human subjects. Europ.J.Clin. Invest. 33, 316-322, 2003. 124. Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R: Effect of Gastric Banding on Aminoterminal Pro-brain Natriuretic Peptide in the Morbidly Obese. Obesity Research 11, 695-698, 2003. 125. Ludvik B, Waldhäusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of Action of Ipomoea Batatas (Caiapo) in Type 2 Diabetic Patients. Metabolism 52, 875-880, 2003. 126. Hanusch-Enserer U, Cauza E, Spak M, Endler G, Dunky A, Tura A, Wagner O, Rosen HR, Pacini G, Prager R: Improvement of Insulin Resistance and Early Atherosclerosis in Patients after Gastric Banding. Obesity Research 12, 284-291, 2004. 127. Kästenbauer T, Irsigler P, Sauseng S, Grimm A, Prager R: The prevalence of symptoms of sensorimotor and autonomic neuropathy in Type 1 and Type 2 diabetic subjects. J Diabetes Complications 18, 27-31, 2004. 128. Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R: Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther. 6, 31-37, 2004. 129. Hanusch-Enserer U, Cauza E, Brabant G, Dunky A, Rosen H, Pacini G, Tuchler H, Prager R, Roden M: Plasma ghrelin in obesity before and after weight loss after laparascopical adjustable gastric banding: J.Clin.Endocrinol.Metab. 89, 3352-3358, 2004. 130. Hanusch-Enserer U, Enserer C, Rosen HR, Prager R: Indikation zur operativen Adipositastherapie. Acta Med Austriaca 31, 125-129, 2004. 131. Stadler M, Prager R: Typ 2 Diabetes mellitus-Screening und Prävention. Acta 132. Kautzky-Willer A, Lechleitner M, Pieber TR, Prager R, Roden M, Wascher TC, Weitgasser R: Therapie mit oralen Antidiabetika. Acta Med Austriaca 31, 162-163, 2004. 133. Kautzky-Willer A, Lechleitner M, Pieber TR, Prager R, Roden M, Wascher TC, Weitgasser R: Insulintherapie. Acta Med Austriaca 31, 164-165, 2004. 134. Edlinger R, Auinger M, Prager R: Diabetische Nephropathie. Acta Med 135. Hermann-Arnhof KM, Hanusch-Enserer U, Kästenbauer T, Publig T, Dunky A, Rosen HR, Prager R, Koller U: N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem 51, 138-143, 2005. 136. Engl J, Hanusch-Enserer U, Prager R, Patsch JR, Ebenbichler C: Das Metabolische Syndrom: Auswirkungen einer ausgeprägten Gewichtsabnahme mittels chirurgischer Intervention. Wien.Klin.Wschr.117, 243-254, 2005. 137. Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P: The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil 86, 1527-1533, 2005. 138. Funk M, Endler G, Exner M, Marculescu R, Endler L, Abrahamian H, Mauler H, Grimm A, Raith M, Mannhalter C, Prager R, Irsigler K, Wagner O: PAI 1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wschr 117/19-20, 707-710, 2005. 139. Prager R: Ezetrol® in der Praxis. J Kardiol 12 (Suppl B), 11-12, 2005. 140. Auinger M, Edlinger R, Prager R: Perionealdialyse bei Patienten mit diabetischer Nephropathie. Wien Klin Wschr 117/6, 1-6, 2005. 141. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R: Efficacy and Safety of Insulin Glulisine in Patients with Type 1 Diabetes. Horm Metab Res 2005; 37: 702-707, 2005. 142. .Stadler M, Anderwald Ch, Karer T, Tura A, Kästenbauer T, Auinger M, Bieglmayer Ch, Wagner O, Kronenberg F, Nowotny P, Pacini G, Prager R: Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation. Diabetes Care 29: 1031-1038, 2006. 143. Kautzky-Willer A, Tura A, Winzer C, Wagner O.F, Ludvik B, Hanusch-Enserer U, Prager R, Pacini G: Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. Diabetes, Obesity and Metabolism Volume 8, Issue 5,Sep 2006. 144. Kästenbauer T, Wassermann J, Krippl E, Prager R, Irsigler K: Measurement of the walking duration with therapeutic shoes in neuropathic diabetic patients by a novel device (Show-me). Diab Care 29/6,1456, 2006. 145. Stadler M, Auinger M, Anderwald C, Kästenbauer T, Kramar R, Feinböck C, Irsigler K, Kronbenberg F, Prager R: Long-Term Mortality and Incidence of Renal Dialysis and Transplantation in Type 1 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism 91(10):3814–3820, 2006. 146. Kollerits B, Auinger M, Reisig V, Kästenbauer T, Lingenhel A, Irsigler K, Prager R, Kronenberg F: Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diab Care 29/7, 1661-63, July 2006. 147. Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, Rumpold H, Gerdov M, Mannhalter C, Prager R, Irisgler K, Wagner O.F: Association of Low-Grade Inflammation with Nephropathy in Type 2 Diabetic Patients: Role of Elevated CRP-Levels and 2 Different Gene-Polymorphisms of Proinflammatory Cytokines. Exp Clin Endocrnol Diabetes 2007 ; 115 : 38-41, 2007. 148. Hanusch-Enserer U, Ghatei Mohammed A., Cuaza E, Bloom Steven R., Prager R, Roden M: Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgery. Wien Klin Wochenschr 119/9-10: 291-296, 2007. 149. M. Anderwald-Stadler, Krebs M, Promintzer M, Mandl M, Bischof MG, Nowotny P, Kästenbauer T, Luger A, Prager R, Anderwald C: Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistanz humans. Am J Physiol Endocrinol Metab. 293(5):E1393-8, 2007. 150. Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, Karnieli E, Assalia A, Prager R, Prager G: Improvement in glycemic control by gastric electrical stimulation (TANTALUS(TM)) in overweight subjects with type 2 diabetes. Surg Endosc. 23(9):1955-60, 2008. 151. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R, Abrahamian H. Riedl M, Pacher R, Luger A, Clodi M: NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J. 29(18):2259-64, 2008. 152. Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K: Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J. 30(12):1516-24, 2009.
Originalarbeiten als kooperierendes Zentrum:

1.
Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 156(4):623-32, 2008. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C. Linn T. Once-daily basal insulin glargine versus thrice-daily prandiale insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371(9618):1073-84, 2008. Erratum in: Lancet 372(9640):718, 2008. Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab. 10(5):387-99, 2008.
Buch und Buchbeiträge:

1.
R. Prager: Diabetesmanagement mit Insulinanaloga, UNI-MED Science, 1. Aufl. 2008. [ISBN 978-3-89599-919-2] M. Anderwald-Stadler, R. Prager: “Typ 2 Diabetes Mellitus”, Buchbeitrag für “Ernährungsmedizin” (Hrsg. Univ.-Prof. Dr. Kurt Widhalm), Verlagshaus der Ärzte, 3. Aufl. 2009. [ISBN 978-3-902552-44-0]

Source: http://www.drprager.at/dl/presse/drprager_publikationen.pdf

Ehpp6(1)sparks

Ethical Human Psychology and Psychiatry, Volume 6, Number 1, Spring 2004 The Ethics and Science of Medicating Children Jacqueline A. Sparks Barry L. Duncan Institute for the Study of Therapeutic Change Prescriptions for psychiatric drugs to children and adolescents have skyrocketed in thepast 10 years. This article presents evidence that the superior effectiveness of stimulantsand

ipd-shippharma.nl

Based on International Medical Guide for Ships, 3rd ed. PRODUCT LIST 2014 IPD SHIPPHARMA, ROTTERDAM I. MEDICIN 1. CARDIO VASCULAR (Heart, blood & veins) Acetosal , 300mg (or IPD: 500mg or Acetylsalicylic acid)Epinephrine HCl 1/1000/1 ml or Adrenaline 1mg/ml 1ml)Atropine sulf inj 1 mg/ml 1ml (double if 0,5 mg/ml)Furosemide (Frusemide) 4ml=40mg (IPD: 20mg/2ml)Furosemide (Frusemide)

Copyright © 2010-2014 Medicament Inoculation Pdf